Craft

Ultimovacs

Stock Price

KR71.4

2021-01-28

Market Capitalization

KR1.7 B

2021-01-28

Ultimovacs Summary

Company Summary

Overview
Ultimovacs is a pharmaceutical company developing immunotherapies against cancer. Its lead product candidate is UV1, a peptide-based vaccine inducing a specific T cell response against the universal cancer antigen telomerase.
Type
Public
Status
Active
Founded
2011
HQ
Oslo, NO | view all locations
Website
https://ultimovacs.com/
Cybersecurity rating
Sectors

Key People

  • Jónas Einarsson

    Jónas Einarsson, Chairman

    • Carlos de Sousa

      Carlos de Sousa, Chief Executive Officer

      • Hans Vassgård Eid

        Hans Vassgård Eid, Chief Financial Officer

        • Ton Berkien

          Ton Berkien, Chief Business Officer

          LocationsView all

          2 locations detected

          • Oslo, Oslo HQ

            Norway

            Ullernchausseen 64-66

          • Uppsala, Uppsala län

            Sweden

            Dag Hammarskjölds Väg 30

          Ultimovacs Financials

          Summary Financials

          Net income (Q3, 2023)
          (kr55.8M)
          Cash (Q3, 2023)
          kr300.3M
          EBIT (Q3, 2023)
          (kr54.7M)
          Enterprise value
          $1.4B

          Footer menu